Related Experiment Video

Updated: Mar 8, 2026

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits
07:34

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

10.4K

Gene-based therapies in patients with critical limb ischemia

Panagiotis Kitrou1, Dimitris Karnabatidis1, Elias Brountzos2

  • 1a Department of Interventional Radiology , Patras University Hospital , Rio , Greece.

Expert Opinion on Biological Therapy
|January 31, 2017
PubMed

Insights

Growth factor gene therapy for critical limb ischemia (CLI) shows potential for treating

Area of Science:

  • Vascular Biology and Regenerative Medicine
  • Gene Therapy
  • Ischemic Disease Treatment

Background:

  • Critical limb ischemia (CLI) is a severe condition with limited treatment options.
  • Revascularization is the primary treatment, but many patients are ineligible.
  • Gene therapy using growth factors for angiogenesis is being explored for 'no-option' CLI patients.

Purpose of the Study:

  • To review current growth factor-based gene therapies for CLI.
  • To discuss challenges and future perspectives in therapeutic angiogenesis for CLI.
  • To contextualize gene therapy within personalized treatment strategies for CLI.

Main Methods:

  • Literature review of studies on growth factor gene delivery for CLI.
  • Analysis of outcomes, challenges, and emerging technologies.
  • Discussion of therapeutic angiogenesis in the framework of tailored CLI therapy.

Main Results:

  • Growth factor therapy for CLI has yielded equivocal and inconclusive results.
  • Gene therapy's potential lies in activating angiogenesis and arteriogenesis at the micro-circulatory level.
  • Personalized treatment approaches are crucial for managing CLI.

Conclusions:

  • Growth factor gene therapy is not a panacea for CLI but can be an adjunct in personalized treatment.
  • Further research and technological advancements are needed to optimize therapeutic angiogenesis.
  • Tailored therapeutic strategies are essential for improving outcomes in CLI patients.
Abstract

Keywords:
AngiogenesisGrowth factorcritical limb ischemiafibroblast growth factorgene therapyhepatocyte growth factorhypoxia inducible growth factorno-option CLI patientsstromal derived growth factorvascular endothelial growth factor

More Related Videos

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

9.3K
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.8K

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.9K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
469
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
56
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
564